靶向IgE的铁蛋白纳米颗粒疫苗在小鼠模型中预防慢性过敏性哮喘
本研究开发了一种将IgE表位肽融合到杂合铁蛋白N端的纳米颗粒抗IgE疫苗,并在慢性过敏性哮喘小鼠模型中进行预防性接种。疫苗诱导高水平抗IgE抗体,降低IgE水平,减轻细支气管周围炎症和黏液产生,并改善炎症相关基因表达。结果表明该疫苗在小鼠中具有保护作用,为过敏性哮喘的防治提供了可转化的策略。
要点
- 铁蛋白纳米颗粒抗IgE疫苗可在小鼠中诱导高水平抗IgE抗体。
- 预防性接种可降低IgE水平并减轻过敏性哮喘关键病理特征。
- 该策略有望成为过敏性哮喘预防和治疗的可转化方案。
核心结论
- 靶向IgE的铁蛋白纳米颗粒疫苗在慢性过敏性哮喘小鼠模型中具有保护作用。
研究设计与样本
- 将IgE来源表位肽与杂合铁蛋白N端基因融合,在大肠杆菌中表达并纯化抗原。
- 在慢性过敏性哮喘小鼠模型中进行预防性接种。
主要发现
- 疫苗诱导高水平抗IgE抗体。
- 疫苗降低IgE水平、减轻细支气管周围炎症和黏液产生,并改善炎症相关基因表达。
临床怎么用
- 目前仅为小鼠模型研究,尚不能直接用于临床实践。
- 提示纳米颗粒抗IgE疫苗可作为过敏性哮喘防治的候选策略。
局限性
- 研究仅在小鼠模型中进行,尚未在人体中验证。
- 原文未报告疫苗的具体剂量、接种程序及长期安全性数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Allergic asthma is a major global health concern owing to its high prevalence and substantial socioeconomic burden. It is characterized by elevated levels of immunoglobulin E (IgE), which plays a pivotal role in the pathophysiology of allergic disorders. Therapeutic anti-IgE antibodies, including omalizumab, have emerged as a validated strategy for the management of IgE-mediated disorders. However, their clinical use requires repeated administration and remains costly. Here, we developed a nanoparticle-based anti-IgE vaccine by genetically fusing an IgE-derived epitope peptide to the N-terminus of a hybrid ferritin. RESULTS: The antigen was expressed in E.coli and purified to homogeneity. Preventive vaccination was conducted in a mouse model of chronic allergic asthma. High levels of anti-IgE antibodies were elicited and ameliorated key features of allergic asthma including the reduction in IgE levels, peribronchiolar inflammation, mucus production, and altered expression of inflammation-related genes. CONCLUSION: The anti-IgE vaccine developed in this study has protective effects in allergic asthma mice, offering a promising translatable strategy for the prevention and treatment of chronic allergic asthma.
引用
- Li W, Liu S, Cui W, et al. A novel ferritin-based nanoparticle vaccine targeting lgE confers protection against chronic allergic asthma in a murine model. Vaccine. 2026. PMID: 42202421. doi:10.1016/j.vaccine.2026.128754
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。